Sector News

Roche to sell U.S. plant to Patheon, saving about 200 jobs

November 29, 2016
Life sciences

Roche has a deal to sell an API plant in South Carolina to CDMO Patheon for a nominal amount, a deal that will save about 200 jobs at the plant in Florence which the Swiss drugmaker was preparing to close.

Durham, NC-based Patheon said it has a definitive agreement to buy the 1,100-acre, 300,000-square-foot facility for what it said is an “immaterial sum, plus the cost of associated inventory and spare parts.”

It also has a multiyear year deal to supply Roche with APIs that will help cover the costs of the facility until the contractor can get new business into it. Patheon said the facility will expand its capacity for manufacturing highly potent compounds, while adding micronization capabilities and commercial spray drying.

“The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” Patheon CEO James Mullen said in a statement.

In an emailed statement, Roche spokeswomen Anja von Treskow said Tuesday the deal with Patheon, which is already a supplier to Roche, is expected to close within 60 days.

Roche said last year it would close the Florence plant, along with plants in Clarecastle, Ireland; Leganes, Spain, and Segrate, Italy, as part of a cost-saving plan that would remove about 1,200 jobs from its payroll. It took a charge of about $1.6 billion for the closures.

While its decision was firm, the Swiss drugmaker said it was trying to sell the plants to save jobs. In June, Greek contract manufacturer Famar said it had struck a deal to take the Leganes, Spain, plant and to supply Roche with APIs.

“In regards to the other sites, we can confirm that we are continuing with our efforts to divest Leganés and Segrate as operational sites to a reputable company, while Clarecastle is in the process of ramping down with production estimated to end in 2019. At this point in time we cannot comment further,” Roche said in its statement.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.